|
Oct 17
|
Penny Stock Kezar Life Sciences Rejects Acquisition Deal From Concentra Biosciences At $1.10/Share, Shelves Mid-Stage Lupus Nephritis Study
|
|
Oct 17
|
Kezar Life Sciences Rejects Concentra Biosciences Takeover Bid, Adopts Rights Plan
|
|
Oct 17
|
Kezar Board Unanimously Rejects Unsolicited Concentra Proposal and Adopts Limited Duration Stockholder Rights Plan
|
|
Oct 17
|
Kezar Life Sciences Announces Positive IDMC Safety Review of PORTOLA Trial of Zetomipzomib in Patients with Autoimmune Hepatitis and Provides PALIZADE Update
|
|
Oct 15
|
What Makes Kezar Life Sciences (KZR) a New Buy Stock
|
|
Oct 10
|
Kezar Confirms Receipt of Unsolicited, Non-Binding Acquisition Proposal
|
|
Oct 8
|
TANG CAPITAL MANAGEMENT LLC Acquires New Stake in Kezar Life Sciences Inc
|
|
Oct 7
|
FDA Put Brakes On Penny Stock Kezar Life Sciences' Mid-Stage Study For Lead Development Candidate After Patient Deaths
|
|
Oct 7
|
FDA places hold on Kezar Life Sciences’ trial for lupus nephritis treatment
|
|
Oct 4
|
Kezar Life Sciences Announces Clinical Hold of Zetomipzomib IND for Treatment of Lupus Nephritis
|
|
May 9
|
Kezar Life Sciences Reports First Quarter 2024 Financial Results and Provides Business Update
|
|
May 6
|
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
|
|
Apr 8
|
13 Best Penny Stocks to Buy According to Billionaire Ken Griffin
|
|
Mar 27
|
From Pennies to Fortunes: 3 Stocks Set to Make Millionaires
|
|
Mar 16
|
Diamonds in the Dust: 3 Penny Stocks Set to Soar 500% by 2026
|
|
Mar 14
|
Kezar Life Sciences Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Update
|
|
Mar 8
|
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
|
|
Dec 18
|
Bull Run Bonanza: Top 3 Penny Stocks Primed for Explosive Growth
|
|
Aug 10
|
Kezar Life Sciences Reports Second Quarter 2023 Financial Results and Provides Business Update
|